Exchange: NASDAQ·Updated 04:15 PM EST

FTHI News

News
all
press releases
Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.
Stocktwits
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.
Stocktwits
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.
Stocktwits

Advertisement|Remove ads.